Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD) (ELASTIC)
Effects of ROFLUMILAST on Markers of Subclinical Atherosclerosis In Stable COPD; the ELASTIC-trial
Sponsor: LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
This PHASE4 trial investigates Chronic Obstructive Pulmonary Disease and Allied Conditions and is currently completed. LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Unknown Status → Completed · Phase: PHASE2 → PHASE4
-
Jun 2018 — May 2019 [monthly]
Unknown Status PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
- Medical University of Vienna
For direct contact, visit the study record on ClinicalTrials.gov .